Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
5961.0000 -31.00 (-0.52%)
NSE Aug 12, 2025 15:31 PM
Volume: 477.8K
 

logo
Divi's Laboratories Ltd.
12 Feb 2024, 12:00AM
5961.00
-0.52%
BOB Capital Markets Ltd.
LICI: Solid quarter; valuations overdone cut to HOLD. ALKEM: Good quarter; cut to SELL on stretched valuations. Monthly Chartbook: Fiscal consolidation to hold key. PWGR: In-line quarter, FY25 capex hiked; maintain BUY. TATACONS: Strong run continues. DIVI: Healthy margin recovery, heady valuations. TPW: Dull quarter; high valuations maintain HOLD. ESCORTS: Weakness persists - maintain SELL. TRCL: Tepid quarter, high capex overhang retain SELL. Metals & Mining: Ferrous read-across: Steel recovery in CY24 - ArcelorMittal
Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.
More from Divi's Laboratories Ltd.
Recommended